Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients;Características clínicas, estadificación y tratamiento de los pacientes con carcinoma hepatocelular en la práctica clínica. Estudio prospectivo de una serie de 136 pacientes

Gastroenterologia y Hepatologia

Volumn 34, Issue 8, 2011, Pages 524-531

  Gómez Rodríguez, Rafael ^a   Romero Gutiérrez, Marta ^a   González de Frutos, Concepción ^a   de Artaza Varasa, Tomás ^a   de la Cruz Perez, Gema ^a   Ciampi Dopazo, Juan José ^a   Lanciego Pérez, Carlos ^a   Gómez Moreno, Ana Zaida ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

BCLC staging; Carcinoma hepatocelular; Cribado; Estadificaci n BCLC; Hepatocellular carcinoma; Surveillance; Tratamiento; Treatment

Indexed keywords

ALCOHOL;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

AGED; ALCOHOLISM; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DIABETES MELLITUS; EARLY DETECTION OF CANCER; ETHANOL; FEMALE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROSPECTIVE STUDIES; PYRIDINES; SCLEROTHERAPY; SPAIN;

EID: 80053982115     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.06.009     Document Type: Article

References (41)

1. El-Serag H.B., Lenhard Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Benvegnu L., Gios M., Boccato S., Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-749.
3. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):S35-S50.
4. Sangiovanni A., Prati G.M., Fasani P., Ronchi G., Romero R., Manini M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-years cohort study of 214 patients. Hepatology 2006, 43:1303-1310.
5. Bosetti C., Levi F., Boffetta P., Lucchini F., Negri E., La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48:137-145.
6. Capocaccia R., Sant M., Berrino F., Simonetti A., Santi V., Trevisani F., et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th Century. Am J Gastroenterol 2007, 102:1661-1670.
7. Yu M.C., Yuan J.M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S72-S78.
8. Wong L.L., Limm W.M., Severino R., Wong L.M. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000, 6:320-325.
9. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003, 39:1076-1084.
10. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
11. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G., Romeo R., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
12. Varela M., Reig M., de la Mata M., Matilla A., Bustamante J., Pascual S., et al. Treatment approach of Hepatocellular Carcinoma in Spain. Analysis of 705 patients from 62 centers. Med Clin (Barc) 2010, 134:569-576.
13. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
14. Bruix J., Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-524.
15. Cillo U., Vitale A., Grigoletto F., Farinati F., Brolese A., Zanus G. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006, 44:723-731.
16. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430.
17. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
18. Forner A., Ayuso C., Isabel Real M., Sastre J., Robles R., Sangro B., et al. Diagnosis and treatment of hepatocellular carcinoma. Med Clin (Barc) 2009, 132:272-287.
19. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
20. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors and screening. Semin Liver Dis 2005, 25:143-154.
21. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010, 42(Suppl 3):S206-S214.
22. Monto A., Wright T.L. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001, 28:441-449.
23. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
24. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533-539.
25. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
26. Santi V., Trevisani1 F., Gramenzi A., Grignaschi A., Mirici-Cappa F., del Poggio P., et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010, 53:291-297.
27. Moreno Planas J.M., Galera Rodenas A.B., Pastor Juan M.R., Velasco Valcarcel A.J., Montealegre Barrejon M., Garcia Nuñez D.F., et al. Low percentage of hepatocellular carcinomas diagnosed inside screening programmes. Gut 2010, 59(Suppl III):A426.
28. Yu S.C., Yeung D.T., So N.M. Imaging features of hepatocellular carcinoma. Clin Radiol 2004, 59:145-156.
29. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001, 34:603-605.
30. Trevisani F., D' Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
31. Bolondi L., Benzi G., Santi V., Gaiani S., Li Bassi S.L., Zironi G., et al. Links relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 1990, 22:190-194.
32. Caturelli E., Bartolucci F., Biasini E., Vigliotti M.L., Andriulli A., Siena D.A., et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002, 97:397-405.
33. Bruix J., Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53:1020-1022.
34. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., Chen Y.C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4cm. Gastroenterology 2004, 127:1714-1723.
35. Shiina S., Teratani T., Obi S., Sato S., Tateishi R., Fujishima T., et al. A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
36. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., Chen Y.C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. Gut 2005, 54:1151-1156.
37. Raman S.S., Aziz D., Chang X., Ye M., Sayre J., Lassman C., et al. Minimizing central bile duct injury during radiofrequency ablation: use of intraductal chilled saline perfusion-initial observations from a study in pigs. Radiology 2004, 232:154-159.
38. Lu D.S., Raman S.S., Limanond P., Aziz D., Economou J., Busuttil R., et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003, 14:1267-1274.
39. Llovet J.M., Vilana R., Bru C., Bianchi L., Salmeron J.M., Boix L., et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124-1129.
40. Livraghi T., Solbiati L., Meloni M.F., Gazelle G.S., Halpern E.F. Goldberg SN.Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226:441-451.
41. Real M.I., Bianchi L., Vilana R., Burrel M., Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010, 52:399-413.